The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA School of Medicine, University of Zagreb, Zagreb, Croatia Department of Internal Medicine, Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA. E-mail: .British Journal of Haematology (impact factor: 4.94). 01/2012; 157(3):401-3. DOI:10.1111/j.1365-2141.2011.08998.x pp.401-3
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.